The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.

Date publication

avril 2019

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc

Tous les auteurs :
Harper DM, Nieminen P, Donders G, Einstein MH, Garcia F, Huh WK, Stoler MH, Glavini K, Attley G, Limacher JM, Bastien B, Calleja E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30955915

Résumé

While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution of CIN2/3 associated with high risk (HR) HPV types.

Mots clés

CIN 2/3, Cervical cancer, HPV, Immunotherapy, Therapeutic vaccine, Women

Référence

Gynecol. Oncol.. 2019 Apr 2;: